Journal of Gastroenterology and Digestive Diseases

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Short Communication - Journal of Gastroenterology and Digestive Diseases (2022) Volume 7, Issue 3

Design and clinical testing for gastric pressure measurement in patients with gastritis.

Xavier M. Henagan*

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India

*Corresponding Author:
Xavier M. Henagan
St Mark?s Hospital,
Harrow, UK and Imperial College London,
London, United Kingdom

Received: 18-Feb-2022, Manuscript No. JGDD-22-111; Editor assigned: 21-Feb-2022, PreQC No. JGDD-22-111 (PQ); Reviewed: 07-Mar-2022, QC No. JGDD-22-111; Revised: 14-Mar-2022, Manuscript No. JGDD-22-111 (R); Published: 18-Mar-2022, DOI:10.35841/jgdd-7.3.114

Citation: Henagan XM. Design and clinical testing for gastric pressure measurement in patients with gastritis. J Gastroenterology Dig Dis. 2022;7(3):114

Visit for more related articles at Journal of Gastroenterology and Digestive Diseases


Gastric pressure

An uncomfortable or sometimes painful feeling of stomach pressure is not unusual, and is actually quite natural, right after a hearty meal - or even several hours afterwards. However, in rare circumstances, persistent gastric pressure or a feeling of being sated or full soon after the start of the meal can suggest a functional gastrointestinal issue. Irritable bowel syndrome and irritable stomach are examples of these. Despite the fact that these problems are not caused by an organic disease, the symptoms can be rather severe. We'll go through how stomach pressure develops, the symptoms it can cause, and what you can do about the uncomfortable feeling in your stomach.

Gastric pressure measurement

Balloon-tipped catheters have been utilised to assess esophageal and stomach pressures to characterise the physiology of the mechanical respiratory system with tremendous effectiveness. Pleural pressure and belly pressure values derived from esophageal and gastric pressure measurements can be used to assess lung and chest wall compliance, as well as work of breathing, respiratory muscle function, and diaphragm paralysis. Although these measurement techniques have primarily been used in the clinical laboratory to improve understanding of basic physiologic mechanisms, they have also been used in clinical situations to diagnose diaphragm paralysis, assess breathing work all through mechanical ventilation, and estimate respiratory compliance [1].


This study establishes the appropriateness of microbubblebased preparations for ingesting and detecting temporal and spatial pressure fluctuation in the human stomach as MRI contrast agents. By adding gas-filled microbubbles into a sodium alginate solution and polymerizing the combination in an aqueous calcium lactate solution, enhanced alginate spheres were created. Using a mechanical cavitational agitation regime, microbubbles with a phospholipid shell and perfluorocarbon gas filling were created. The increased alginate spheres' NMR signal changes in response to externally applied pressure were recorded and compared to alginate spheres without microbubbles. Healthy individuals were also used in in vivo studies to evaluate the pressure changes in the stomach. The MR signal changes in the contrast agent have a linear sensitivity of about 40% per bar, whereas there is no discernible signal change in the control gas-free spheres. In simulated stomach settings, including at body temperature, this novel contrast agent also displays outstanding stability. The signal shift seen in the meal within the antrum region is between 5% and 10%, according to in vivo investigations; however it appears to be caused by both pressure changes and partial volume distortions [2].

Proton pump inhibitors (PPIs) have become more popular in the United States and around the world in the last 30 years. PPIs are one of the most commonly used off-label medications, as well as for approved indications (peptic ulcer illness, gastroesophageal reflux disease (GERD), Helicobacter pylori eradication regimens, and stress ulcer prophylaxis) (25-70% of total). PPIs are being used indefinitely by an increasing number of patients with moderate to severe gastroesophageal reflux disease. While multiple studies suggest that PPIs are still useful and safe after 5 years, there is little data available for patients who have been on them for more than 10 years.

There have been an increasing number of reports recently, based mostly on observational/epidemiological research, raising concerns about safety and side effects. Some of these safety concerns are connected to the long-term effects of chronic hypergastrinemia, which occurs in all patients taking chronic PPIs, while others are related to the hypo-/ achlorhydria that is common with chronic PPI medication, and others have unknown origins. Because of the scarcity of long-term PPI therapy data (>10-20 years), these issues have sparked substantial debate. The Zollinger-Ellison syndrome (ZES) is characterised by ectopic gastrin production from a neuroendocrine tumour, which causes severe acid hypersecretion and necessitates lifelong antisecretory treatment with PPIs, which are the preferred medicines. Because a long-term cure is not attainable in 30% of ZES patients, these individuals have life-long hypergastrinemia and must take PPIs for the rest of their lives. Patients with ZES have been suggested as a good model for the long-term effects of hypergastrinemia in humans, as well as the effects/sideeffects of very long-term PPI medication. The findings from ZES research into these contentious concerns with regard to chronic PPI usage in non-ZES patients are reviewed in this paper, with a focus on data from prospective long-term studies of ZES patients [3].

Clinical testing

Peptic ulcer and gastric malignancy, such as gastric carcinoma and mucosa-associated lymphoid tissue lymphoma, can advance or be aggravated by Helicobacter pylori-associated gastritis. Predicting who may acquire cancer is still a clinical difficulty. The molecular understanding of pathways linked to the transition of the normal gastric epithelium to malignancy, as well as traditional histologic criteria, are potential approaches to addressing this issue. In an ideal world, molecular screening methods would be available as noninvasive tests, such as the examination of markers detectable in blood samples, but this is not the case right now. Molecular markers that correspond with cancer risk, on the other hand, can be studied in the epithelium after endoscopic biopsy and can be useful in identifying those who are at risk, especially when paired with other risk factors for gastric cancer [4].


  1. Benditt JO. Esophageal and gastric pressure measurements. Respir Care. 2005;50(1):68-75.
  2. Indexed at, Google Scholar

  3. Abdurakman E, Bencsik M, Cave GWV, et al. Design and testing of microbubble-based MRI contrast agents for gastric pressure measurement. Magn Reson Med. 2020;83(3):1096-108.
  4. Indexed at, Google Scholar, Crossref

  5. Lee L, Ramos-Alvarez I, Ito T, et al. Insights into effects/risks of chronic hypergastrinemia and lifelong ppi treatment in man based on studies of patients with Zollinger-Ellison Syndrome. Int J Mol Sci.2019;20(20):5128.
  6. Indexed at, Google Scholar, Crossref

  7. Sepulveda AR. Molecular testing of Helicobacter pylori-associated chronic gastritis and premalignant gastric lesions: clinical implications. J Clin Gastroenterol. 2001;32(5):377-82.
  8. Indexed at, Google Scholar, Crossref

Get the App